特殊人群的他汀类药物应用

doi:10. 3969/j. issn. 1002-1949. 2016. 07. 019

Chinese Journal of Critical Care Medicine

2016, Vol. 36

Issue (7): 661-666 DOI: 10. 3969/j. issn. 1002-1949. 2016. 07. 019

Statin use in special populations

YANG Shuang, LI Bi-cheng, WANG Yan, TIAN Ye

The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

Abstract
Figure/Table
References (44)
Related Citation (15)

Download: PDF (970 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract At present, statins are widely used in atherosclerotic diseases because of their anti-inflammatory and reduction of cholesterol levels effects, especially in primary and secondary prevention of coronary atherosclerotic cardiovascular disease（ASCVD）. But its application related side effects, such as statin- related myonosus, liver injury, increased type 2 diabetes mellitus, increased kidney damage and so on, leading the application of statins into a low ebb once. Especially in special populations, such as women, the elderly, patients with diabetes, chronic kidney disease patients, the value of the application is more to be discussed. This article will review the application of statins in the special population.

Received: 25 January 2016

Corresponding Authors: TIAN Ye, E-mail：yetian@ems.hrbmu.edu.cn

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Shuang
	LI Bi-cheng
	WANG Yan
	TIAN Ye

Cite this article:

YANG Shuang,LI Bi-cheng,WANG Yan, et al. Statin use in special populations[J]. Chinese Journal of Critical Care Medicine, 2016, 36(7): 661-666.

URL:

http://www.cnemergency.org.cn/EN/10. 3969/j. issn. 1002-1949. 2016. 07. 019 OR http://www.cnemergency.org.cn/EN/Y2016/V36/I7/661

［1］ Sarah L, Gary W, Robert C, et al. Blood cholesterol and vascular mortality by age,sex,and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths［J］. Lancet, 2007, 370（370）:1829-1839. ［2］ Updesh B, Mukesh S, Param S, et al. Effects of statins on progression of coronary artery disease as measured by intravascular ultrasound［J］. J Clin Hypertens, 2011,13（7）:492-496. ［3］ Qing L, Song-Bai D, Shuang X, et al. Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention: a clinical study［J］. Med Clin, 2013, 140（12）:532-536. ［4］ Nielsen SF, Nordestgaard BG. Negative statin- related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality:a nationwide prospective cohort study［J］. Eur Heart J, 2016,37（11）:908-916. ［5］ Mosca L, Mochari- Greenberger H, Dolor RJ, et al. Twelve- year follow-up of American women’sawareness of cardiovascular disease risk and barriers to heart health［J］. Circ Cardiovasc Qual Outcomes, 2010, 3（2）:120-127. ［6］ Yang W, Xiao J, Yang Z, et al. Serum lipids and lipoproteins in Chinese men and women［J］. Circulation, 2012,125（18）:2212-2221. ［7］ Bhattacharjee S, Findley PA, Sambamoorthi U. Understanding Gender Differences in Statin Use among Elderly Medicare Beneficiaries［J］. Drugs Aging, 2012,29（12）:971-980. ［8］ Virani SS, Woodard LCD, Ramsey DJ, et al. Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease［J］. Am J Cardiol, 2015, 115（1）:21-26. ［9］ Katsiki N, Banach M. Statin use and risk of diabetes mellitus in postmenopausal women［J］. Clin Lipidol, 2012,7（3）:267-270. ［10］ Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta- analysis［J］. Preventive Cardiol, 2010,13（2）:84-90. ［11］ Ginsberg HN, Elam MB, Lovato LC, et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus［J］. N Engl J Med,2010, 362（17）:1563-1574. ［12］ Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials［J］. Lancet, 2015,385（9976）:1397-1405. ［13］ Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin（JUPITER）and meta-analysis of women from primary prevention trials［J］. Circulation, 2010,121（9）:1069-1077. ［14］ Grundy SM. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia［J］. J Clin Lipidol, 2013,7（6）:561-565. ［15］ Strandberg TE, Laura K, Alpo V. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review［J］.JAMA, 2014,312（11）:1136-1144. ［16］ Gianluigi S, Gotto AM, Stefania P, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis［J］. J Am Coll Cardiol, 2013,62（22）:2090-2099. ［17］ Ridker PM, Eleanor D, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein［J］. New Engl J Med, 2008,359（21）:534. ［18］ James S, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease（PROSPER）: a randomised controlled trial. Commentary［J］. Lancet, 2002,360（2）:1623-1630. ［19］ Rabar S, Harker M, O'Flynn N, et al. Lipid modification and car⁃diovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance［J］. BMJ, 2014,349:g4356. ［20］ Ganda OP. Deciphering cholesterol treatment guidelines: a clinician's perspective［J］. JAMA, 2015, 313（2）:605-614. ［21］ Naveed S, David P, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta- analysis of randomised statin trials［J］. Lancet, 2010, 375（9716）:735-742. ［22］ David P, Paul W, Murphy SA, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis［J］. JAMA, 2011, 305（24）:2556-2564. ［23］ Swerdlow DI, David P, Kuchenbaecker KB, et al. HMG- coenzyme A reductase inhibition, type 2 diabetes, and bodyweight:evidence from genetic analysis and randomised trials［J］. Lancet, 2015, 385（14）:351-361. ［24］ Koh KK, Quon MJ, Han SH. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients［J］. Atherosclerosis, 2009, 204（2）:483-490. ［25］ Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients ［J］. J Atheroscleros Thromb,2005, 12（2）:111-119. ［26］ Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4（SLC2A4）: implications in glycaemic control［J］. Diabetologia,2006, 49（8）:1881-1892. ［27］ Henriksbo BD, Lau TC, Cavallari JF, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance［J］.Diabetes, 2014, 63（11）:3742-3747. ［28］ Jacobson TA, Ito MK, Maki KC, et al. National Lipid association recommendations for patient- centered management of dyslipidemia: part 1-full report［J］. J Clin Lipidol, 2015, 9（2）:129-169. ［29］ Fellstr MBC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis［J］.New Engl J Med, 2009, 360（14）:1395-1407. ［30］ Geng Q, Ren J, Song J, et al. Meta- analysis of the effect of statins on renal function［J］. Am J Cardiol, 2014, 114（4）:562-570. ［31］ Jacobson TA. Statin Safety: Lessons from new drug applications for marketed statins［J］. Am J Cardiol, 2006, 97（8）:44C-51C. ［32］ Colin B, Landray MJ, Christina R, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease（study of heart and renal protection）: a randomised placebo- controlled trial［J］. Lancet, 2011, 377（9784）: 2181-2192. ［33］ Han YL, Zhu GY, Xu B, et al. Short-term statin therapy for prevention of contrast induced-acute kidney injury in patients with diabetes and chronic kidney disease［J］. Chin Med J（Engl）,2015,128（6）:784-789. ［34］ Tonelli M, Wanner C. Kidney disease:improving global outcomes lipid guideline development work group members.lipid management in chronic kidney disease: synopsis of the kidney disease:improving global outcomes 2013 clinical practice guideline［J］.Ann Intern Med, 2014,160（3）：182-189. ［35］ Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals［J］. J Hepatol,2015, 63（3）:705-712. ［36］ Tolosa L, Carmona A, Castell JV, et al. High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins［J］. Arch Toxicol, 2015, 89（10）:1847-1860. ［37］ Bays H, Cohen DE, Chalasani N, et al. An assessment by the statin liver safety task force: 2014 update［J］. J Clin Lipid,2014, 8（3）:S47-S57. ［38］ Stroes ES, Thompson PD, Alberto C, et al. Statin- associated muscle symptoms: impact on statin therapy- European atherosclerosis society consensus panel statement on assessment, aetiology and management［J］. Eur Heart J, 2015, 36（17）:1012-1022. ［39］ Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study［J］. J Clin Lipidol, 2014, 8（1）:69-76. ［40］ Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors［J］. Neuromuscul Disord, 2014, 24（1）:4-15. ［41］ Stroes ES, Thompson PD, Alberto C, et al. Statin- associated muscle symptoms: impact on statin therapy- European atherosclerosis society consensus panel statement on assessment, aetiology and management［J］. Eur Heart J, 2015, 36（17）:1012-1022. ［42］ Mospan CM. Are statins protective or harmful to cognitive function［J］. JAAPA, 2016, 29（1）:11-12. ［43］ Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallelgroup trial［J］. J Am Coll Cardiol, 2013, 62（13）:1154-1162. ［44］ Leander K, Mälarstig A, Van't Hooft FM, et al. Circulating PCSK9 predicts future risk of cardiovascular events indepen⁃dently of established risk factors［J］. Circulation, 2016,133（13）:1230-1239.